Evidence mapPaperPMID 39061909Full record

ArticleAntioxidants (Basel, Switzerland)2024

Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.

Milena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, Róża Derkacz, Klaudia Stempa, Piotr Baszuk, Marta Bryśkiewicz, Cezary Cybulski, Tadeusz Dębniak, Jacek Gronwald and 17 more

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Genomic insights into the recent evolution and biodiversity of Italian sheep breeds.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Milena MatuszczakDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0001-8050-1507
Adam KiljańczykDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0009-0000-9398-3592
Wojciech MarciniakRead-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.ORCID 0000-0001-7270-0063
Róża DerkaczRead-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.ORCID 0000-0002-2904-5259
Klaudia StempaDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Piotr BaszukDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0002-0676-2597
Marta BryśkiewiczDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Tadeusz DębniakDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0002-3506-8932
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0002-3643-2871
Tomasz HuzarskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Marcin LenerDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.
Anna JakubowskaDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0002-5650-0501
Marek SzwiecDepartment of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland.ORCID 0000-0001-6981-6356
Małgorzata Stawicka-NiełacnaDepartment of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland.ORCID 0000-0003-3076-9892
Dariusz GodlewskiOPEN, Kazimierza Wielkiego 24 Str., 61-863 Poznań, Poland.
Artur PrusaczykMedical and Diagnostic Center, 08-110 Siedlce, Poland.
Andrzej JasiewiczGenetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego St, 36-200 Brzozów, Poland.ORCID 0000-0002-1581-8791
Tomasz KluzDepartment of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland.ORCID 0000-0002-4798-3986
Joanna Tomiczek-SzwiecDepartment of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland.ORCID 0000-0001-8908-6610
Ewa Kilar-KobierzyckaDepartment of Oncology, District Specialist Hospital, Leśna 27-29 St, 58-100 Świdnica, Poland.
Monika SiołekHolycross Cancer Center, Artwińskiego 3 St, 25-734 Kielce, Poland.
Rafał WiśniowskiRegional Oncology Hospital, Wyzwolenia 18 St, 43-300 Bielsko Biała, Poland.ORCID 0009-0007-3438-6270
Renata PosmykDepartment of Clinical Genetics, Medical University in Bialystok, 15-089 Bialystok, Poland.
Joanna Jarkiewicz-TretynNon-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toruń, Poland.
Rodney ScottMedical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle; Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia.ORCID 0000-0001-7724-3404
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.ORCID 0000-0003-2931-3003

Funding

program of Minister of Science and Higher Education"Regional Initiative of Excellence" in years 2019-2022 Grant No. 002/RID/2018/19
6 · The paper itself

Abstract

Pathogenic mutations in BRCA1 (BReast CAncer gene 1) confer high risks of both breast (up to 70%) and ovarian (up to 40%) cancers. Zinc (Zn) and copper (Cu) are essential for various physiological functions, including antioxidant reactions. Their balance, reflected in the Zn/Cu ratio, plays a crucial role in maintaining redox homeostasis, which is vital for cancer prevention. This study examines the antioxidant properties of Zn and Cu, specifically focusing on the blood Zn/Cu ratio as a potential marker for cancer risk among BRCA1 mutation carriers. The study cohort consisted of 989 initially unaffected women, followed up for 7.5 years. Blood samples were analyzed using inductively coupled plasma mass spectrometry. Although individual Zn and Cu levels did not significantly correlate with overall cancer risk, those women with a Zn/Cu ratio above 6.38 experienced a significantly lower cancer risk than women with a ratio below this cut-off point. This suggests that the Zn/Cu ratio may be a valuable biomarker for cancer prevention in this high-risk group. Given the increased cancer risk in BRCA1 mutation carriers, optimizing Zn and Cu levels through dietary and active interventions could provide a preventive strategy.

Indexed as

blood levelsBRCA1BRCA1 mutationbreast cancercancer riskcoppergermline mutationmodifiersovarian cancerpropective cohortzinc

Identifiers

PMID39061909
PMCPMC11273827

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.